The outlook for the global Alpha Thalassemia Market remains overwhelmingly positive, underpinned by a continuous influx of venture capital into biotechnology firms focused on rare blood disorders. The inherent limitations and high costs associated with traditional management methods, such as regular blood transfusions and chelation therapy, have spurred an urgent need for more permanent...